BNTC — Benitec Biopharma Balance Sheet
0.000.00%
- $405.67m
- $311.19m
- 43
- 20
- 90
- 50
Annual balance sheet for Benitec Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 19.8 | 4.06 | 2.48 | 50.9 | 97.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.025 | 0.003 | 0.055 | 0.229 | 0.033 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 20.6 | 4.82 | 3.73 | 51.7 | 98.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.577 | 0.993 | 0.613 | 0.449 | 0.991 |
| Other Long Term Assets | |||||
| Total Assets | 21.4 | 5.97 | 4.46 | 52.2 | 99.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.37 | 2.53 | 3.98 | 4.92 | 1.8 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.37 | 3.09 | 4.26 | 4.96 | 2.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 20 | 2.88 | 0.202 | 47.2 | 97.3 |
| Total Liabilities & Shareholders' Equity | 21.4 | 5.97 | 4.46 | 52.2 | 99.6 |
| Total Common Shares Outstanding |